Eckert & Ziegler SE Showcases Notable Q3 Earnings Growth

In the third quarter of 2026, Eckert & Ziegler SE reported a robust return to growth, with adjusted EBIT increasing by 25% year-over-year to €19.3 million. The company's group sales rose by 6% year-over-year, reaching €79.6 million. This performance was bolstered by a favourable medical product mix and improved profitability within intellectual property, expanding the margin by 3.8 percentage points to 24.2%.

The medical segment continued to be the primary driver of earnings, with a 46% year-over-year rise in adjusted EBIT to €11.3 million, despite challenges in the lower-margin plant engineering sector. The company has maintained its full-year guidance, indicating anticipated Q4 sales of €91 million and an adjusted EBIT of €27.4 million.

Therapeutic isotopes present a promising growth avenue, with Lu-177 sales expected to increase significantly over the next few years. With sector consolidation, the valuation remains modest, offering an attractive opportunity in the growing radiopharma market.